

Date of preparation: 17 September 2026

Issuer's abbreviated name: SYNEKTIK SA

Current report: 44/2026 ESPI

Subject: Information on the conclusion of a significant sale agreement

Legal basis: Article 17 Section 1 of MAR – confidential information

Body of the report:

Time of publication: 01:53 p.m.

The Management Board of Synektik SA ("Company") reports that the Company has learned of the conclusion of significant agreement by the subsidiary doing business as SYNEKTIK Baltic SIA with its registered office in Riga, Latvia with SA Põhja-Eesti Regionaalhaigla (Northern Estonia Hospital Foundation) with its registered office at Sütiste tee 19, 13419 Tallinn, Estonia (Hospital).

The agreement pertains to the option of sale, delivery, installation and commissioning of the da Vinci minimally invasive surgery robotic system for the Hospital with personnel training and warranty maintenance care, the option of post-warranty maintenance care for a period of 9 years as well as on-going supplies of instruments for a period of 10 years.

This agreement was concluded as a result of a proceeding conducted under Estonian public procurement law and its net value is EUR 9,406,284.52.

The robotic system may be delivered to the Hospital within 24 months. The warranty period for system delivery is 12 months from signing the final acceptance report. The other clauses in the agreement do not deviate from the standards generally used in contracts of this type.

The signing of this agreement has been deemed to be significant by the Management Board of Synektik SA since its net value brings 5% of the equity of the Synektik Group disclosed in the last periodic report, meaning that it exceeds the level prescribed internally in the Company in its individual reporting standards. The proceeds generated from the project will impact sales results in the 2025–2035 financial years.

Persons representing the Issuer:

Cezary Kozanecki – President of the
Management Board